このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

ネオアジュバントニボルマブと切除可能なNSCLCのイピリムマブ(Galaxy 3) (GALAXY 3)

2026年11月5日 更新者:Shuben Li、The First Affiliated Hospital of Guangzhou Medical University

ネオアジュバントニボルマブと切除可能な非小細胞肺癌におけるイピリムマブ

Neoadjuvant immunotherapy followed by surgery has emerged as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). However, conventional chemotherapy components may increase treatment-related toxicity, particularly in elderly populations. Additionally, the efficacy of preoperative immunochemotherapy for patients with PD-L1 expression <1% remains to be improved. Emerging evidence has demonstrated that the combination of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) provides superior responses in the treatment of advanced NSCLC. However, the safety and efficacy of this strategy in the neoadjuvant setting remain controversial. Therefore, this single-arm clinical trial aims to evaluate the safety and feasibility of neoadjuvant nivolumab plus ipilimumab followed by surgery in treating locally advanced and resectable NSCLC.

調査の概要

詳細な説明

Lung cancer remains the leading cause of cancer-related death globally. Neoadjuvant immunotherapy followed by surgery has been emerged as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). Numerous clinical trials highlighted the efficacy of preoperative immunochemotherapy, including remarkably shrinking the primary lesion, eliminating micrometastases and ultimately contributing to survival outcomes. Notably, studies also demonstrated neoadjuvant immunochemotherapy increased the access of modified surgery and enhanced survival prognosis of patients with locally advanced NSCLC (IIIB).

Despite these advances, certain limitations remain. Conventional chemotherapy components may elevate treatment-related toxicity, particularly in elderly populations. Additionally, the efficacy of preoperative immunochemotherapy for patients with PD-L1<1% remained to be improve. Emerging evidences demonstrated that nivolumab (anti-PD-1) combine with ipilimumab (antiCTLA-4) provided superior response for the treatment of advanced NSCLC patients. However, the safety and efficacy of this strategy in the neoadjuvant setting remain controversial. Therefore, this single-arm clinical trial aims to evaluate the safety and feasibility of neoadjuvant nivolumab plus ipilimumab followed by surgery in treating locally advanced and resectable NSCLC. The study will enroll 69 eligible participants, with the primary endpoint being pathological complete response (pCR) rate following neoadjuvant therapy.

研究の種類

介入

入学 (推定)

69

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

      • Guangzhou、中国、510120
        • 募集
        • First Affiliated Hospital of Guangzhou Medical University
        • コンタクト:
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~80年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Informed consent must be signed.
  2. At least 18 years of age.
  3. Histologically or cytologically confirmed non-small cell lung cancer (without EGFR, ALK mutation).
  4. Have measurable and clinical stage II-IIIA with no known PD-L1 expression or PD-L1 ≤ 1%.
  5. disease eligible for surgery.
  6. No previous systematic therapy or radiotherapy.
  7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  8. At least one measurable lesion.
  9. No major organ dysfunction, including liver, kidney, and cardiac function.

Exclusion Criteria:

  1. Patients with active autoimmune disease or history of autoimmune disease.
  2. Patients have received other treatment for non-small cell lung cancer or for any other malignancy.
  3. History of allergy to study drug components.
  4. Pregnant or breast-feeding.
  5. Any mental or psychological condition that would prevent the patient from completing the study or understanding the patient information.
  6. Patients who have other malignancies.
  7. History of major surgery or serious injury within the past 3 months.
  8. HIV, HBV, HCV infection or active pulmonary tuberculosis.
  9. Vaccination within 4 weeks prior to the start of the study.
  10. Presence of underlying medical conditions that, in the investigator's judgment, could increase the risk associated with study drug administration or interfere with the assessment of toxicity and adverse events.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Neoadjuvant treatment

Patients with IIA-IIIB NSCLC will received 2-3 cycles of neoadjuvant Nivolumab (3 mg/kg intravenously (i.v.), every 3 week) plus Ipilimumab (1 mg/kg i.v., every 6 week).

Surgery will be performed within 4 to 6 weeks after completion of preoperative therapy.

After the second cycles treatment, contrast-enhanced chest CT will be performed to evaluate the tumor.

This study evaluates the safety and efficacy of neoadjuvant nivolumab plus ipilimumab for IIA-IIIB NSCLC. Based on preliminary trial results, this study proposes a new treatment regimen.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Pathological Complete Response (PCR)
時間枠:Within 2 weeks after surgery

Pathological complete response is predefined as no residual viable tumor cells in primary tumor and lymph nodes.

Within 2 weeks after surgery

二次結果の測定

結果測定
メジャーの説明
時間枠
3-year Event-Free Survival (3-year EFS)
時間枠:From neoadjuvant treatment to the date of death, recurrence, progression, or the last follow-up (assessed up to 3 years).

The starting point for EFS was the initiation of neoadjuvant treatment. The endpoint for EFS was defined as the date of death, recurrence, progression, or the last follow-up.

From neoadjuvant treatment to the date of death, recurrence, progression, or the last follow-up (assessed up to 3 years).
Major Pathological Response (MPR)
時間枠:Within 2 weeks after surgery

Major pathological response defined as less than 10% of viable tumor cells in primary tumor.

Within 2 weeks after surgery
Safety (Rate of grade 3 and higher grade treatment-related adverse events (TRAEs))
時間枠:Between the last dose of neoadjuvant treatment and surgery (assessed up to 30 days)

Adverse events will be evaluated and recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0).

Between the last dose of neoadjuvant treatment and surgery (assessed up to 30 days)
Radiological Response
時間枠:Between the last dose of neoadjuvant treatment and surgery

Radiographic response will be evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

Between the last dose of neoadjuvant treatment and surgery
Postoperative complications
時間枠:After the surgery assess to 90 days

Postoperative complications will be evaluated and recorded after the surgery following Clavien-Dindo grade. The minimum and maximum values were grade I-V, and the higher scores mean a worse outcomes.

After the surgery assess to 90 days
Intraoperative bleeding
時間枠:Up to approximately 20 weeks

Intraoperative bleeding was assessed and recorded by the surgical team. Blood loss was estimated by measuring suction canister volume and weighing surgical sponges, subtracting irrigation fluid.

Up to approximately 20 weeks
The Quality of Life
時間枠:From the Day 1 to at least 90 days after surgery

The quality of life will be evaluated and recorded according to the EORTC QLQ-C30. The minimum and maximum values were 0-100, and the higher scores mean a better outcome.

From the Day 1 to at least 90 days after surgery
Duration of surgery
時間枠:Up to approximately 20 weeks

Duration of surgery is the time spent in surgery.

Up to approximately 20 weeks
Hospital Stay
時間枠:Up to approximately 20 weeks

Hospital Stay is the length of inpatient time spent in hospital.

Up to approximately 20 weeks
Feasibility (Completion rate of neoadjuvant treatment and surgery)
時間枠:From date of treatment allocation until surgery, assessed up to 5 months

Propotion of patients who complete neoadjuvant treatment and receive surgery within 42 days after neoadjuvant treatment

From date of treatment allocation until surgery, assessed up to 5 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年6月19日

一次修了 (推定)

2030年3月31日

研究の完了 (推定)

2030年10月31日

試験登録日

最初に提出

2025年3月30日

QC基準を満たした最初の提出物

2025年4月11日

最初の投稿 (実際)

2025年4月15日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月9日

QC基準を満たした最後の更新が送信されました

2026年11月5日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する